sio Weekly Update MultiBriefs
Contact Us
Media Kit

Browse Categories

Browse by Date

Search past issues
Search products and services

It's time to renew your SIO membership for 2022 and lock in your continued access to member-only benefits—from exclusive education opportunities to advocacy representation through IO Awareness Week. Explore our new renewal options and simplify your membership renewals...


SIO recently announced the launch of the society's first...


Don't forget to register for the SIO2022 Annual Scientific Meeting! Be the first of your colleagues to...


This study sought to evaluate the safety and efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with oxaliplatin plus fluorouracil and leucovorin (FOLFOX)-based...

source: Journal of Hepatocellular Carcinoma via Dovepress

The treatment response to initial conventional transarterial chemoembolization (cTACE) is essential for the prognosis of patients with hepatocellular carcinoma (HCC)....

source: Journal of Hepatocellular Carcinoma via Dovepress

Although transarterial chemoembolization (TACE) is the most widely used treatment for intermediate-stage, unresectable hepatocellular carcinoma (HCC), it is only effective in a subset of...

source: Cell Reports via PubMed


Powered by MultiBriefs
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063

Subscribe to IO Insights

*First Name:
*Last Name:
Street Address:
State / Province:
Zip / Postal Code:
Are you a member of SIO? Yes   No
Privacy Policy